TY - JOUR T1 - Genome-wide association studies of cognitive and motor progression in Parkinson’s disease JF - medRxiv DO - 10.1101/2020.05.07.20084343 SP - 2020.05.07.20084343 AU - Manuela MX Tan AU - Michael A Lawton AU - Edwin Jabbari AU - Regina H Reynolds AU - Hirotaka Iwaki AU - Cornelis Blauwendraat AU - Sofia Kanavou AU - Miriam I Pollard AU - Leon Hubbard AU - Naveed Malek AU - Katherine A Grosset AU - Sarah L Marrinan AU - Nin Bajaj AU - Roger A Barker AU - David J Burn AU - Catherine Bresner AU - Thomas Foltynie AU - Nicholas W Wood AU - Caroline H Williams-Gray AU - John Hardy AU - Michael A Nalls AU - Andrew B Singleton AU - Nigel M Williams AU - Yoav Ben-Shlomo AU - Michele TM Hu AU - Donald G Grosset AU - Maryam Shoai AU - Huw R Morris Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/08/2020.05.07.20084343.abstract N2 - Background There are currently no treatments that stop or slow the progression of Parkinson’s disease (PD). Case-control genome-wide association studies (GWASs) have identified variants associated with disease risk, but not progression.Objective To identify genetic variants associated with PD progression in GWASs.Methods We analysed three large, longitudinal cohorts: Tracking Parkinson’s, Oxford Discovery, and the Parkinson’s Progression Markers Initiative. We included clinical data for 3,364 patients with 12,144 observations (mean follow-up 4.2 years). We used a new method in PD, following a similar approach in Huntington’s disease, where we combined multiple assessments using a principal components analysis to derive scores for composite, motor, and cognitive progression. These scores were analysed in linear regressions in GWASs. We also performed a targeted analysis of the 90 PD risk loci from the latest case-control meta-analysis.Results There was no overlap between variants associated with PD risk, from case-control studies, and PD age at onset versus PD progression. The APOE ε4 tagging variant, rs429358, was significantly associated with the rate of composite and cognitive progression in PD. No single variants were associated with motor progression. However in gene-based analysis, variation across ATP8B2, a phospholipid transporter related to vesicle formation, was nominally associated with motor progression (p=5.3 × 10−6).Conclusions This new method in PD improves measurement of symptom progression. We provide strong evidence that the APOE ε4 allele drives progressive cognitive impairment in PD. We have also identified other loci of interest, such as ATP8B2 for motor progression, which need to be replicated in further studies.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02881099Funding StatementM.M.X.T. is supported Parkinson’s UK. M.A.L. is supported by Parkinson’s UK. E.J. is supported by the Medical Research Council UK. R.H.R. supported through the award of a Leonard Wolfson Doctoral Training Fellowship. N.B. has received payment for advisory board attendance from UCB, Teva Lundbeck, Britannia, GSK, Boehringer and honoraria from UCB Pharma, GE Healthcare, Lily Pharma, Medtronic. He has received research grant support from GE Healthcare, Wellcome Trust, Medical Research Council, Parkinson’s UK and National Institute for Health Research. R.A.B. has received grants from Parkinson's UK, NIHR, Cure Parkinson's Trust, Evelyn Trust, Rosetrees Trust, MRC, Wellcome Trust, and EU along with payment for advisory board work from Oxford Biomedica, Living Cell Technologies, Fujifilm Cellular Dynamics Inc, Nova Nordisk, BlueRock Therapeutics, Sana Biotherapeutics, Aspen Neuroscience and UCB along with honoraria from Wiley and Springer for books and editorial work.D.J.B. has received grants from NIHR, Wellcome Trust, GlaxoSmithKline Ltd, Parkinson’s UK and Michael J Fox Foundation. T.F. has received grants from Michael J Fox Foundation, Cure Parkinson’s Trust, Brain Research trust, John Black Charitable Foundation, Rosetrees trust and honoraria for speaking at meetings from Bial, Profile Pharma and Medtronic. N.W.W. is supported by the MRC and NIHR UCLH Biomedical research centre. C.H.W-G is supported by a RCUK/UKRI Research Innovation Fellowship awarded by the Medical Research Council (MR/R007446/1), by the NIHR Cambridge Biomedical Research Centre Dementia and Neurodegeneration Theme (Grant Reference Number 146281), and by the Cambridge Centre for Parkinson-Plus. M.A.N. reports that this work was done under a consulting contract with National Institutes of Health, he also consults for Lysosomal Therapeutics Inc, Neuron23, and Illumina. J.H. is supported by the UK Dementia Research Institute which receives its funding from DRI Ltd, funded by the UK Medical Research Council, Alzheimer’s Society and Alzheimer’s Research UK. He is also supported by the MRC, Wellcome Trust, Dolby Family Fund, National Institute for Health Research University College London Hospitals Biomedical Research Centre. Y.B-S. has received grant funding from the MRC, NIHR, Parkinson’s UK, NIH and ESRC. N.M.W. is supported by Parkinson’s UK. M.T.H. receives grants from Parkinson's UK, Oxford NIHR Biomedical Research Centre, and MJFF and is an adviser to the Roche Prodromal Advisory and Biogen Digital advisory boards. D.G.G. has received grants from Michael’s Movers, The Neurosciences Foundation, and Parkinson’s UK, and honoraria from UCB Pharma and GE Healthcare, and consultancy fees from Acorda Therapeutics. H.R.M. is supported by the PSP Association, CBD Solutions, Drake Foundation, the Medical Research Council UK, Parkinson's UK, and Cure Parkinson's Trust. All other authors did not declare any funding sources that directly contributed to this study. M.M.X.T. takes responsibility for the integrity of the data and the accuracy of the data analysis.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymised data from Tracking Parkinson’s and Oxford Discovery are available to researchers on application. Please apply via the project coordinators (tracking-parkinsons{at}glasgow.ac.uk and parkinsons.discovery{at}nhs.net respectively). The PPMI data is publicly available on application (https://www.ppmi-info.org/access-data-specimens/download-data/). Code is available at https://github.com/huw-morris-lab/PD-PCA-progression-GWAS. https://github.com/huw-morris-lab/PD-PCA-progression-GWAS FUMAFunctional Mapping and Annotation of GWASHDHuntington’s DiseaseGWASGenome-wide Association StudyLDLinkage DisequilibriumMDS-UPDRSMovement Disorder Society Unified Parkinson’s Disease Rating ScaleMoCAMontreal Cognitive AssessmentPCAPrincipal Components AnalysisPDParkinson’s DiseasePPMIParkinson’s Progression Markers InitiativeSNPSingle Nucleotide PolymorphismSDStandard Deviation ER -